| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Anesthesiology, Weill Medical College of Cornell University, New York, New York, USA.
Address correspondence to: Dr. Klaus Kjaer, Department of Anesthesiology, Weill Medical College of Cornell University, 525 E 68th Street, M-325, New York, NY 10021, USA. Phone: 212-746-2781; Fax: 212-746-8563; E-mail: kkjaer{at}hotmail.com
| Abstract |
|---|
|
|
|---|
Methods: One hundred and twenty-three healthy women carrying a singleton fetus and scheduled for elective Cesarean delivery under spinal anesthesia were randomized to receive either sodium citrate 30 mL po and saline 2 mL iv (sodium citrate group), or water 30 mL po and famotidine 20 mg iv (famotidine group). Spinal anesthesia consisted of 1.6 mL of 0.75% bupivacaine (12 mg), fentanyl 20 µg, and preservative-free morphine 200 µg. Patients were asked to rate the degree of nausea present at one and five minutes after spinal placement, at the time of uterine exteriorization, and upon arrival to the recovery room. At each time point, the patients systolic blood pressure and heart rate were recorded.
Results: At all recorded intervals, the average degree of nausea was greater in the sodium citrate group compared to the famotidine group. The frequency of nausea was also greater in the sodium citrate group compared with the famotidine group (37% vs 14% respectively, P < 0.05) five minutes after establishment of spinal anesthesia. The frequencies of nausea were not significantly different between groups at other time periods.
Conclusion: Nausea is more common during Cesarean delivery in women who receive oral sodium citrate rather than iv famotidine for aspiration prophylaxis.
| Introduction |
|---|
|
|
|---|
Before elective Cesarean delivery, gastric fluid pH increases comparably with either famotidine or oral sodium citrate.35 Although sodium citrate is commonly used, many patients dislike its taste and some patients complain of nausea.6,7
We hypothesized that women having elective Cesarean delivery under spinal anesthesia would have a higher incidence of nausea when receiving sodium citrate rather than water and famotidine immediately prior to surgery. We designed a randomized trial to test this hypothesis.
| Methods |
|---|
|
|
|---|
Spinal anesthesia was introduced in the sitting position, and the patient was immediately positioned supine with left uterine displacement. To control for systemic hypotension as a potential confounding variable, an infusion of ephedrine 5 mg·min1 and phenylephrine 20 µg·min1 was initiated immediately upon positioning the patient supine. Blood pressure was measured at one-minute intervals, and the drug infusion was then discontinued either ten minutes after spinal placement, or once systolic blood pressure exceeded the patients baseline value. Thereafter, additional boluses of ephedrine 5 mg and phenylephrine 20 µg were given only as required to maintain systolic blood pressure at baseline values.
The degree of nausea was assessed using the same scale at four time points: one minute after spinal placement, five minutes after spinal placement, at the time of uterine exteriorization (the uterus was exteriorized in all study patients), and once the patient reached the recovery room. At each interval, the patients systolic blood pressure and heart rate were recorded. Hypotension was defined as systolic blood pressure
100 mmHg. Dolasetron 12.5 mg iv was given if needed for persistent nausea and vomiting after exteriorization of the uterus.
Statistical analysis
With an expected incidence of intraoperative nausea of 33% and an expected reduction in that rate by 10% by the omission of sodium citrate, a necessary sample size of 55 patients per group was required to achieve 50% statistical power with a 5%
.8 All patients with nausea scores of 2, 3, 4, or 5 were considered to have nausea. Differences in the incidence of nausea and vomiting were compared in two ways. First, mean nausea scores were compared at each time point, using Students t test for significance. Recognizing the potential confounding influence of hypotension, average systolic blood pressures were also compared at each time point. Second, the Pearson Chi-square test was used to compare the incidence of nausea at each time point. Again, the incidence of hypotension was compared at each time point. Finally, logistic regression was used to adjust for the effects of hypotension, to determine the odds ratio of developing nausea with sodium citrate at each time point. Two-tailed probability values were used throughout. Calculations were performed using SPSS 12.0.1 for Windows (Chicago, IL, USA). A P-value < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
While our study is the first to document a significant increase in the incidence of nausea with oral sodium citrate, it has long been known that these solutions are considered highly unpleasant by most patients. Several products have been marketed as better-tasting sodium citrate solutions; however, none has succeeded in capturing the market, and no product, in our opinion, tastes better than Bicitra®.
Hypotension is a strong trigger for nausea during Cesarean delivery. We administered a mixture of ephedrine and phenylephrine preemptively to prevent and treat hypotension in order to minimize the effect of systemic hypotension on the results. The observed incidence of hypotension (
22% at all time points studied) was lower than that usually reported during spinal anesthesia for Cesarean delivery (5585%).13,14 We believe this is why the incidence of nausea in the sodium-citrate-treated patients (737%) was lower than the incidence reported in other studies (6376%).6,7
The results of our study differ from those of the only other randomized study on this subject. Palmer et al. found that oral Bicitra® did not affect the incidence of nausea during Cesarean delivery.8 However, Palmer et al. studied fewer patients, and included patients receiving epidural, as well as spinal anesthesia. In addition, hypotension was not controlled as aggressively as was the case in the current investigation. It is also possible that the famotidine suppressed nausea in our study.
Histamine-2 blockers have been used extensively before Cesarean delivery.3,4,15 In one randomized trial, famotidine 20 mg given to mothers one hour before Cesarean delivery did not affect neonatal gastric acidity, liver function tests, or Apgar scores. The umbilical venous: maternal venous ratio was 0.64 ± 0.13.16 Histamine-2 blockers, including famotidine, are frequently used in infants to treat gastroesophageal reflux or prevent stress ulceration.17,18
In conclusion, nausea during Cesarean delivery is more frequent in women receiving oral sodium citrate rather than iv famotidine. Therefore, we recommend the preoperative use of a histamine-2 blocker rather than oral sodium citrate to neutralize maternal gastric acidity in parturients scheduled for elective Cesarean delivery under spinal anesthesia.
| Footnotes |
|---|
Accepted for publication December 6, 2005. Revision accepted March 23, 2006.
| References |
|---|
|
|
|---|
2 Cooper GM, McClure JH. Maternal deaths from anaesthesia. An extract from Why Mothers Die 20002002, the Confidential Enquiries into Maternal Deaths in the United Kingdom: Chapter 9: Anaesthesia. Br J Anaesth 2005; 94: 41723.
3 Lin CJ, Huang CL, Hsu HW, Chen TL. Prophylaxis against acid aspiration in regional anesthesia for elective cesarean section: a comparison between oral single-dose ranitidine, famotidine and omeprazole assessed with fiberoptic gastric aspiration. Acta Anaesthesiol Sin 1996; 34: 17984.[Medline]
4 Elhakim M, Abd El-Megid W, Metry A, El-hennawy A, El-Queseny K. Analgesic and antacid properties of i.m. tramadol given before caesarean section under general anaesthesia. Br J Anaesth 2005; 95: 8115.
5 Dewan DM, Floyd HM, Thistlewood JM, Bogard TD, Spielman FJ. Sodium citrate pretreatment in elective cesarean section patients. Anesth Analg 1985; 64: 347.
6 Stein DJ, Birnbach DJ, Danzer BI, Kuroda MM, Grunebaum A, Thys DM. Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. Anesth Analg 1997; 84: 3425.[Abstract]
7 Fujii Y, Tanaka H, Toyooka H. Prevention of nausea and vomiting with granisetron, droperidol and metoclopramide during and after spinal anaesthesia for caesarean section: a randomized, double-blind, placebo-controlled trial. Acta Anaesthesiol Scand 1998; 42: 9215.[Medline]
8 Palmer AW, Waugaman WR, Conklin KA, Kotelko DM. Does the administration of oral Bicitra before elective cesarean section affect the incidence of nausea and vomiting in the parturient? Nurse Anesth 1991; 2: 12633.[Medline]
9 Wong CA, Loffredi M, Ganchiff JN, Zhao J, Wang Z, Avram MJ. Gastric emptying of water in term pregnancy. Anesthesiology 2002; 96: 1395400.[Medline]
10 Hagberg C, Ezri T, Abouleish E. Etiology and incidence of endotracheal intubation following spinal anesthesia for cesarean section. Isr Med Assoc J 2001; 3: 6536.[Medline]
11 Garry M, Davies S. Failure of regional blockade for caesarean section. Int J Obstet Anesth 2002; 11: 912.[Medline]
12 Hawkins JL, Koonin LM, Palmer SK, Gibbs CP. Anesthesia-related deaths during obstetric delivery in the United States, 19791990. Anesthesiology 1997; 86: 27784.[Medline]
13 Rout CC, Rocke DA, Levin J, Gouws E, Reddy D. A reevaluation of the role of crystalloid preload in the prevention of hypotension associated with spinal anesthesia for elective cesarean section. Anesthesiology 1993; 79: 2629.[Medline]
14 Riley ET, Cohen SE, Rubenstein AJ, Flanagan B. Prevention of hypotension after spinal anesthesia for cesarean section: six percent hetastarch versus lactated Ringers solution. Anesth Analg 1995; 81: 83842.[Abstract]
15 Schneck H, Scheller M, Wagner R, von Hundelshausen B, Kochs E. Anesthesia for cesarean section and acid aspiration prophylaxis: a German survey. Anesth Analg 1999; 88: 636.
16 Doi H, Maruta H, Kudoh I, et al. Placental transfer and effects of famotidine on neonates. J Anesth 1991; 5: 27680.[Medline]
17 Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003; 17: 1097107.[Medline]
18 James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol 1998; 38: 108995.[Abstract]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |